In meningiomas with adverse clinical outcomes and loss of NF2, the Wnt pathway may be activated by epigenetic silencing of endogenous Wnt inhibitors24, but there does not appear to be an epigenetic basis of Wnt pathway activation in meningiomas with favorable clinical outcomes and expression of NF27. This evidence concerns the gene NF2 and meningioma.